Cervical Cancer Screening Follow-Up Doubles With Structured Support, Global Analysis Finds

A sweeping global analysis has found that structured interventions—ranging from text-message reminders to patient navigation programs—can roughly double the odds that women who test positive during cervical cancer screening actually return for the follow-up care that could save their lives. The systematic review and meta-analysis, published in BMC Medicine, synthesizes evidence from 25 studies encompassing 142,298 women across 11 countries on six continents, and offers the most comprehensive picture yet of where the world’s cervical cancer elimination effort is stalling and what can be done about it.

The findings arrive at a critical moment. In 2020, the World Health Organization launched its global strategy to eliminate cervical cancer as a public health problem, built on the so-called 90-70-90 targets: 90 percent of girls fully vaccinated against human papillomavirus by age 15, 70 percent of women screened with a high-performance test in their lifetime, and 90 percent of women with cervical disease receiving appropriate treatment. While considerable attention has focused on vaccination and screening coverage, the third target—treatment—has received far less scrutiny. Yet a screening program that identifies precancerous lesions but fails to shepherd women through diagnosis and treatment saves no one. Public health researchers call this the screening cascade, and the losses at each step, from a positive screen to colposcopy attendance to diagnostic confirmation to definitive treatment, are often dramatic, particularly in low- and middle-income countries where the majority of cervical cancer deaths occur.

Leading the new analysis, Xinhua Jia of Chongqing University Cancer Hospital and the National Cancer Center in Beijing, together with colleagues including senior author Youlin Qiao, set out to answer two questions that have frustrated program designers for years. First, how effective are interventions at improving follow-up completion among screen-positive women? Second, and more subtly, does the effectiveness of those interventions depend on what kind of intervention is delivered, or on where in the cascade the intervention is applied? The distinction matters enormously for resource allocation: if SMS reminders work as well as intensive patient navigation, cash-strapped health systems in low- and middle-income settings could favor cheaper digital tools. But if effect sizes shrink predictably at later cascade steps, a single-point intervention may never be sufficient.

The team searched PubMed, Embase, CINAHL, and the Cochrane Library from their inception through 31 March 2026, registered the review prospectively with PROSPERO under identifier CRD420251031531, and followed PRISMA 2020 reporting standards. From 33 studies that met inclusion criteria, 25 studies covering 142,298 women in 11 countries across six continents provided data for the primary meta-analysis. The investigators used Hartung–Knapp–Sidik–Jonkman random-effects models as their primary statistical approach, a method favored for its better control of false-positive findings when the number of studies is modest and heterogeneity is high. Subgroup analyses examined study design, intervention type, country income level, the presence of a digital component, and, in exploratory fashion, the position of each intervention along the screening cascade. Publication bias was assessed with Egger’s regression test, trim-and-fill analysis, and the PET-PEESE method, and certainty of the evidence was graded using the GRADE framework.

The headline result was striking: structured interventions were associated with significantly higher odds of follow-up completion, with an odds ratio of 2.03 (95 percent confidence interval 1.71 to 2.41). In practical terms, a woman in an intervention arm had roughly twice the odds of completing her follow-up as a woman receiving usual care. Heterogeneity was substantial, with an I-squared value of 83.1 percent, indicating that the true effect likely varies considerably across settings and populations—a reality captured by the wide prediction interval of 1.11 to 3.73, which suggests that in some settings the effect could be nearly negligible while in others it could be nearly fourfold. Importantly, the direction of effect was consistent across study designs, with subgroup odds ratios ranging from 1.80 to 2.21 whether the underlying evidence came from randomized controlled trials or observational studies.

The authors did not shy away from the field’s uncomfortable methodological realities. Egger’s test indicated substantial publication bias, with a P value below 0.001, meaning small studies with null results are likely underrepresented in the published literature. When the team applied trim-and-fill and PET-PEESE adjustments, the pooled estimate attenuated to an odds ratio between 1.73 and 1.88, and a restricted analysis of the 15 studies judged to be at low or moderate risk of bias yielded an odds ratio of 1.87 (95 percent confidence interval 1.55 to 2.26). Even after these corrections, the signal remained robust and clinically meaningful. The authors translated the adjusted estimate into absolute terms: for a program with a baseline follow-up completion rate of 30 percent—a sobering but realistic figure in many high-burden settings—an intervention with an odds ratio of about 1.8 would lift completion to roughly 44 percent, an absolute gain of about 14 percentage points.

Perhaps the most consequential finding concerned what did not predict effect size. Subgroup differences by intervention type, by the presence of a digital component, and by country income level were all statistically nonsignificant, with P values exceeding 0.25. In other words, the analysis found no clear evidence that expensive, labor-intensive navigation programs outperform lightweight SMS reminders, nor that interventions work better in wealthy countries than in resource-constrained ones. For ministries of health weighing competing investments, this is an encouraging message: what appears to matter is not the sophistication of the delivery modality but the presence of some structured, deliberate mechanism connecting a screen-positive woman to her next appointment.

Where the effect did vary was along the cascade itself. In exploratory analyses, effect sizes differed significantly by cascade-step position, with a P value of 0.006. Interventions were most effective at getting women in the door for colposcopy, where the odds ratio reached 2.35, and least effective at achieving full diagnostic resolution, where the odds ratio fell to 1.46. The pattern suggests a gradient in which structured support is powerful at overcoming the logistical and informational barriers of a single next step—scheduling a colposcopy, arranging transport, reminding a patient of a date—but loses traction as the pathway lengthens and multiplies. Reaching diagnostic resolution may require several consecutive hurdles: biopsy, histopathological confirmation, and a treatment decision, each of which presents its own opportunity for attrition. The implication is sobering for program designers who treat follow-up as a single problem to be solved once.

The GRADE assessment rated the overall certainty of the evidence as very low, a reminder that much of the underlying literature rests on observational designs with inherent vulnerabilities to confounding and selection effects. The authors are candid about this limitation and about the substantial between-study heterogeneity, and their conclusion is correspondingly measured: the association between structured interventions and improved follow-up is consistent, but the field lacks the rigorous, randomized evidence—particularly from low- and middle-income settings—needed to prescribe precisely which intervention packages should be deployed at which cascade steps. They call explicitly for layered, step-specific interventions that prioritize the distal, most leak-prone portions of the diagnostic pathway, where gains appear hardest to achieve and where the 90 percent treatment target will ultimately be won or lost.

With the 2030 deadline for the WHO elimination targets fast approaching, the study reframes the treatment gap not as a monolithic shortfall but as a series of discrete, addressable losses. Its quantitative core—an adjusted odds ratio near 1.8 and an absolute gain of roughly 14 percentage points at low baseline completion rates—gives policymakers a realistic benchmark for what structured follow-up support can deliver, while its cascade-step analysis warns against complacency at the final mile. As cervical cancer continues to claim hundreds of thousands of lives annually, most of them in countries with the weakest screening infrastructure, the message is clear: finding the lesions is no longer the hardest part. Getting women through the door, and then through every door after that, is where elimination will be decided.

Subject of Research: Effectiveness of structured interventions in improving follow-up completion along the cervical cancer screening cascade toward WHO 90-70-90 elimination targets

Article Title: Closing the cervical screening cascade gap toward WHO 90-70-90 elimination targets: A systematic review and meta-analysis of 25 studies in 11 countries

Article References: Jia, X., Da, X., Sun, R., Shi, J., Gao, C., & Qiao, Y. (2026). Closing the cervical screening cascade gap toward WHO 90-70-90 elimination targets: A systematic review and meta-analysis of 25 studies in 11 countries. BMC Medicine. https://doi.org/10.1186/s12916-026-05221-z

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05221-z

Keywords: cervical cancer, WHO elimination targets, screening cascade, meta-analysis, patient navigation, colposcopy, follow-up completion, HPV screening, low- and middle-income countries, publication bias, BMC Medicine, global health